The effect of finasteride in men with benign prostatic hyperplasia
2002; Lippincott Williams & Wilkins; Volume: 167; Issue: 2 Part 2 Linguagem: Inglês
10.1016/s0022-5347(02)80349-4
ISSN1527-3792
AutoresG J Gormley, Elizabeth Stoner, Reginald C. Bruskewitz, Julianne Imperato‐McGinley, Patrick C. Walsh, John D. McConnell, Gerald L. Andriole, Jack Geller, Bruce Bracken, Joyce S. Tenover, E. Darracott Vaughan, Frances Pappas, Alice Taylor, Bruce Binkowitz, Jennifer Ng,
Tópico(s)Hormonal and reproductive studies
ResumoNo AccessJournal of Urology1 Feb 2002The effect of finasteride in men with benign prostatic hyperplasia Gleen J. Gormley, M.D., Ph.D. Elizabeth Stoner, M.D. Reginald C. Bruskewitz, M.D. Julianne Imperato-McGinley, M.D. Patrick C. Walsh, M.D. John D. McConnell, M.D. Gerald L. Andriole, M.D. Jack Geller, M.D. Bruce R. Bracken, M.D. Joyce S. Tenover, M.D., Ph.D. E. Darracott Vaughan, M.D. Frances Pappas, M.S. Alice Taylor, M.S. Bruce Binkowitz, M.S. Jennifer Ng, andS.D. The Finasteride Study Group Gleen J. GormleyGleen J. Gormley , Elizabeth StonerElizabeth Stoner , Reginald C. BruskewitzReginald C. Bruskewitz , Julianne Imperato-McGinleyJulianne Imperato-McGinley , Patrick C. WalshPatrick C. Walsh , John D. McConnellJohn D. McConnell , Gerald L. AndrioleGerald L. Andriole , Jack GellerJack Geller , Bruce R. BrackenBruce R. Bracken , Joyce S. TenoverJoyce S. Tenover , E. Darracott VaughanE. Darracott Vaughan , Frances PappasFrances Pappas , Alice TaylorAlice Taylor , Bruce BinkowitzBruce Binkowitz , Jennifer NgJennifer Ng , and The Finasteride Study Group View All Author Informationhttps://doi.org/10.1016/S0022-5347(02)80349-4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Background. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5α-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. Methods. In a double-blind study, we evaluated the effect of two doses offinasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. Results. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P <0.001), an increase of 1.6 ml per second (22 percent, P <0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P <0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups. Conclusions. The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction. References 1. : Natural history of benign prostatic hypertrophy. In: Benign prostatic hypertrophy. Edited by . New York: Springer-Verlag1983: 5. Google Scholar 2. : Origins, distribution and risk of benign prostatic hypertrophy. In: Benign prostatic hypertrophy. Edited by . New York: Springer-Verlag1983: 10. Google Scholar 3. : The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol1985; 121: 78. Google Scholar 4. : Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med1989; 320: 1120. Google Scholar 5. : Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol1998; 141: 68. Google Scholar 6. : The effect of nafareline acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med1987; 317: 599. Google Scholar 7. : Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science1974; 186: 1213. Google Scholar 8. : Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineosrotal hypospadias. N Engl J Med1974; 291: 944. Google Scholar 9. : Biochemistry and pharmacology of 5α-reductase inhibitors. In: Pharmacology and clinical uses of inhibitors of hormone secretion and action. Edited by . London: Baílière Tindall1987: 308. Google Scholar 10. : The role of 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. In: . Edited by . Philadelphia: J.B.^Lippincott1991: 436. Google Scholar 11. : Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl1989; 10: 259. Google Scholar 12. : Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab1990; 70: 1136. Google Scholar 13. : The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol1992; 147: 1298. Link, Google Scholar 14. : The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol1990; 37: 375. Google Scholar 15. : A new look at bladder neck obstruction by the Food and Drug Administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg1976; 68: 29. Google Scholar 16. : Development of nomograms for application of uroflowmetry. In: Benign prostatic hypertrophy. Edited by . New York: Springer-Verlag1983: 528. Google Scholar 17. : Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide. Urology1989; 34: 10. Google Scholar 18. : Critical evaluation of trans-urethral resection and incision of the prostate. Prostate Suppl1990; 3: 27. Google Scholar 19. : The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol1990; 143: 533. Link, Google Scholar 20. : Male peak urinary flow rate: relationship to volume voided and age. J Urol1979; 122: 210. Link, Google Scholar © 2002 by American Urological Association, IncFiguresReferencesRelatedDetailsCited byTANGEN C, GOODMAN P, CROWLEY J and THOMPSON I (2018) Statistical Design Issues and Other Practical Considerations for Conducting Phase III Prostate Cancer Prevention TrialsJournal of Urology, VOL. 171, NO. 2S, (S64-S67), Online publication date: 1-Feb-2004. Volume 167Issue 2 Part 2February 2002Page: 1102-1107 Advertisement Copyright & Permissions© 2002 by American Urological Association, IncMetricsAuthor Information Gleen J. Gormley From the Merck Research Laboratories, Rahway, N.J. More articles by this author Elizabeth Stoner From the Merck Research Laboratories, Rahway, N.J. More articles by this author Reginald C. Bruskewitz University of Wisconsin, Madison More articles by this author Julianne Imperato-McGinley New York Hospital, New York More articles by this author Patrick C. Walsh Johns Hopkins Hospital, Baltimore More articles by this author John D. McConnell University of Texas, Dallas More articles by this author Gerald L. Andriole Washington University, St. Louis More articles by this author Jack Geller Mercy Hospital and Medical Center, San Diego, Calif. More articles by this author Bruce R. Bracken University of Cincinnati Medical Center, Cincinnati More articles by this author Joyce S. Tenover Harborview Medical Center, Seattle More articles by this author E. Darracott Vaughan New York Hospital, New York More articles by this author Frances Pappas From the Merck Research Laboratories, Rahway, N.J. More articles by this author Alice Taylor From the Merck Research Laboratories, Rahway, N.J. More articles by this author Bruce Binkowitz From the Merck Research Laboratories, Rahway, N.J. More articles by this author Jennifer Ng From the Merck Research Laboratories, Rahway, N.J. More articles by this author The Finasteride Study Group More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)